{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:24:15Z","timestamp":1789439055824,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,6]]},"DOI":"10.7759\/cureus.66322","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T23:42:46Z","timestamp":1722987766000},"source":"Crossref","is-referenced-by-count":8,"title":["Imeglimin for Type 2 Diabetes Mellitus: Its Efficacy and Insight Into the Potential Benefit for Renal and Liver Function"],"prefix":"10.7759","author":[{"given":"Asuka","family":"Uto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ishinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Asaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tanahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Meshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview","volume":"37","author":"Nathan DM","year":"2014","unstructured":"Nathan DM, DCCT\/EDIC Research Group. The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014, 37:9-16. 10.2337\/dc13-2112","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton IM","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, et al.. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321:405-12. 10.1136\/bmj.321.7258.405","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/2468-8827.184853","article-title":"WHO global report on diabetes: a summary","volume":"1","author":"Roglic G","year":"2016","unstructured":"Roglic G. WHO global report on diabetes: a summary. Int J Noncommun Dis. 2016, 1:3-8. 10.4103\/2468-8827.184853","journal-title":"Int J Noncommun Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0894","article-title":"The pathogenesis of diabetic nephropathy","volume":"4","author":"Dronavalli S","year":"2008","unstructured":"Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008, 4:444-52. 10.1038\/ncpendmet0894","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis EJ","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993, 329:1456-62. 10.1056\/NEJM199311113292004","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.58","article-title":"The RAAS in the pathogenesis and treatment of diabetic nephropathy","volume":"6","author":"Ruggenenti P","year":"2010","unstructured":"Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol. 2010, 6:319-30. 10.1038\/nrneph.2010.58","journal-title":"Nat Rev Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen BL","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, et al.. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019, 7:845-54. 10.1016\/S2213-8587(19)30256-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman SL","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018, 24:908-22. 10.1038\/s41591-018-0104-9","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher G","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020, 69:1691-705. 10.1136\/gutjnl-2020-320622","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1220","article-title":"Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model","volume":"64","author":"Vial G","year":"2015","unstructured":"Vial G, Chauvin MA, Bendridi N, et al.. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015, 64:2254-64. 10.2337\/db14-1220","journal-title":"Diabetes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0763","article-title":"Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes (times 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial","volume":"44","author":"Dubourg J","year":"2021","unstructured":"Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K. Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes (times 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial. Diabetes Care. 2021, 44:952-9. 10.2337\/dc20-0763","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14613","article-title":"Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (times 2): a 52-week, open-label, multicentre phase 3 trial","volume":"24","author":"Dubourg J","year":"2022","unstructured":"Dubourg J, Fouqueray P, Quinslot D, Grouin JM, Kaku K. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (times 2): a 52-week, open-label, multicentre phase 3 trial. Diabetes Obes Metab. 2022, 24:609-19. 10.1111\/dom.14613","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14642","article-title":"Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (times 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period","volume":"24","author":"Reilhac C","year":"2022","unstructured":"Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (times 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab. 2022, 24:838-48. 10.1111\/dom.14642","journal-title":"Diabetes Obes Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01589-9","article-title":"Imeglimin hydrochloride: first approval","volume":"81","author":"Lamb YN","year":"2021","unstructured":"Lamb YN. Imeglimin hydrochloride: first approval. Drugs. 2021, 81:1683-90. 10.1007\/s40265-021-01589-9","journal-title":"Drugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard A","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al.. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007, 46:32-6. 10.1002\/hep.21669","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin L","year":"2003","unstructured":"Sandrin L, Fourquet B, Hasquenoph JM, et al.. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003, 29:1705-13. 10.1016\/j.ultrasmedbio.2003.07.001","journal-title":"Ultrasound Med Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova K","year":"2017","unstructured":"Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al.. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017, 128:40-50. 10.1016\/j.diabres.2017.03.024","journal-title":"Diabetes Res Clin Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018, 41:917-28. 10.2337\/dci18-0007","journal-title":"Diabetes Care"},{"key":"ref20","unstructured":"Japan diabetes report 2000-2045. (2021). Accessed. July 31, 2024: https:\/\/www.diabetesatlas.org\/data\/en\/country\/101\/jp.html."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S003","article-title":"3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024. Diabetes Care. 2024, 47:S43-51. 10.2337\/dc24-S003","journal-title":"Diabetes Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.11.012","article-title":"Vascular complications of diabetes: mechanisms of injury and protective factors","volume":"17","author":"Rask-Madsen C","year":"2013","unstructured":"Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013, 17:20-33. 10.1016\/j.cmet.2012.11.012","journal-title":"Cell Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.5.1814","article-title":"Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy","volume":"90","author":"Yamamoto T","year":"1993","unstructured":"Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993, 90:1814-8. 10.1073\/pnas.90.5.1814","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2174\/138161208784139710","article-title":"Role of AGEs in diabetic nephropathy","volume":"14","author":"Fukami K","year":"2008","unstructured":"Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des. 2008, 14:946-52. 10.2174\/138161208784139710","journal-title":"Curr Pharm Des"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.016","article-title":"Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease","volume":"48","author":"Chalasani N","year":"2008","unstructured":"Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A, NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol. 2008, 48:829-34. 10.1016\/j.jhep.2008.01.016","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi H","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, et al.. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022, 6:120-32. 10.1002\/hep4.1696","journal-title":"Hepatol Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.126417","article-title":"Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"56","author":"Yoneda M","year":"2007","unstructured":"Yoneda M, Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, Nakajima A. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007, 56:1330-1. 10.1136\/gut.2007.126417","journal-title":"Gut"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas US","year":"2019","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019, 25:101084. 10.1016\/j.redox.2018.101084","journal-title":"Redox Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0135-z","article-title":"Cellular death, reactive oxygen species (ROS) and diabetic complications","volume":"9","author":"Volpe CMO","year":"2018","unstructured":"Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018, 9:119. 10.1038\/s41419-017-0135-z","journal-title":"Cell Death Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/273168-imeglimin-for-type-2-diabetes-mellitus-its-efficacy-and-insight-into-the-potential-benefit-for-renal-and-liver-function","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T23:42:50Z","timestamp":1722987770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/273168-imeglimin-for-type-2-diabetes-mellitus-its-efficacy-and-insight-into-the-potential-benefit-for-renal-and-liver-function"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.66322","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}